1KJ:F:F-10X GENOMICS DL -00001 (EUR)

COMMON STOCK | Health Information Services |

Last Closing

USD 21.03

Change

+2.23 (+11.83)%

Market Cap

USD 2.31B

Volume

550.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
L0T:F GE HEALTHCARE TECH.INC.

+1.53 (+1.93%)

USD 35.91B
2HE:F Healthequity Inc

-1.00 (-1.42%)

USD 6.16B
4YC:F M3 INC.

+0.10 (+1.15%)

USD 5.81B
6HL0:F R1 RCM Inc

+0.10 (+0.79%)

USD 5.45B
9EH:F Evolent Health Inc

+0.40 (+1.46%)

USD 3.16B
6JM:F JMDC INC.

N/A

USD 1.93B
OC9:F Omnicell Inc

-1.80 (-4.50%)

USD 1.78B
19P:F Phreesia Inc

-0.20 (-0.92%)

USD 1.26B
4LL:F Teladoc Inc

+0.05 (+0.60%)

USD 1.25B
1XZ:F Ping An Healthcare and Technol..

+0.02 (+1.57%)

USD 1.21B

ETFs Containing 1KJ:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -59.34% 18% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.34% 18% F 6% D-
Trailing 12 Months  
Capital Gain -49.33% 33% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.33% 30% F 12% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.59% 27% F 14% F
Dividend Return -16.59% 24% F 13% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.31% 59% D- 51% F
Risk Adjusted Return -65.57% 35% F 17% F
Market Capitalization 2.31B 92% A 69% C-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.